文献速递前列腺增生与排尿功能障碍男科与性医学

代谢综合征与吸烟与男性良性前列腺增大患者夜尿症风险增加相关

Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-12-04

该研究纳入492例下尿路症状/良性前列腺增大患者,评估吸烟、代谢综合征与夜尿症的关系。中重度夜尿症占43.1%,代谢综合征患者中60.5%有中重度夜尿症,当前吸烟者中52%有中重度夜尿症。多因素分析显示年龄、前列腺体积、代谢综合征和吸烟与夜尿症严重程度相关。

要点

  • 代谢综合征患者中60.5%存在中重度夜尿症,显著高于无代谢综合征者。
  • 当前吸烟者中52%存在中重度夜尿症,显著高于非吸烟者。
  • 多因素分析中代谢综合征OR 2.509,吸烟OR 1.690,均与夜尿症严重程度相关。

核心结论

  • 代谢综合征和吸烟使下尿路症状/良性前列腺增大患者中重度夜尿症风险加倍。
  • 建议评估下尿路症状/良性前列腺增大患者的吸烟与代谢状态。

研究设计与样本

  • 2009年起连续纳入下尿路症状/良性前列腺增大患者,共492例,中位年龄68岁(IQR 61/74),中位BMI 26.5 kg/m2(IQR 24/29)。
  • 症状采用国际前列腺症状评分(IPSS)评估,代谢综合征按成人治疗组III标准定义,中重度夜尿症定义为夜间排尿次数≥2次。

主要发现

  • 中重度夜尿症见于212例(43.1%)患者。
  • 代谢综合征诊断147例(29.9%),其中89例(60.5%)主诉中重度夜尿症(p=0.001)。
  • 当前吸烟者187例(38%),其中99例(52%)存在中重度夜尿症(p=0.034)。
  • 中重度夜尿症患者年龄更大(p=0.001)且前列腺体积更大(p=0.003)。
  • 多因素分析中,年龄(OR 1.067/年,95%CI 1.036-1.098;p=0.001)、前列腺体积(OR 1.011/ml,95%CI 1.003-1.019;p=0.006)、代谢综合征(OR 2.509,95%CI 1.571-4.007;p=0.001)和吸烟(OR 1.690,95%CI 1.061-2.693;p=0.027)与夜尿症严重程度相关。

关键数值与推荐

  • 代谢综合征按成人治疗组III标准定义。
  • 中重度夜尿症定义为夜间排尿次数≥2次。

临床怎么用

  • 原文建议评估下尿路症状/良性前列腺增大患者的吸烟与代谢状态。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the relationship between cigarette smoking, metabolic syndrome (MetS) and nocturia in patients with lower urinary tract symptoms (LUTS) and benign prostatic enlargement (BPE). METHODS: From 2009 onward, a consecutive series of patients with LUTS/BPE were enrolled. Symptoms were assessed using the International Prostate Symptom Score (IPSS). Age, body mass index (BMI), smoker status, prostate volume (PV), prostate-specific antigen (PSA) levels, fasting glucose levels, triglyceride levels, and high-density lipoprotein levels were recorded. MetS was defined according to Adult Treatment Panel III criteria. Moderate/severe nocturia was defined as nocturnal micturition episodes ≥2. RESULTS: Overall 492 patients were enrolled with median age and BMI of 68 years (IQR 61/74) and 26.5 kg/m2 (IQR: 24/29), respectively. Moderate/severe nocturia was reported in 212 (43.1%) patients. MetS was diagnosed in 147 (29.9%) patients and out of them 89 (60.5%) complained moderate/severe nocturia (p = 0.001). Overall 187 (38%) patients were current smokers and out of them 99 (52%) presented moderate/severe nocturia(p = 0.034). Patients with moderate/severe nocturia were older (p = 0.001) and with larger prostate volume (p = 0.003). On multivariate analysis, age (OR: 1.067 per year, 95% CI: 1.036-1.098; p = 0.001), PV (OR: 1.011 per ml, 95% CI: 1.003-1.019; p = 0.006), MetS (OR: 2.509, 95% CI: 1.571-4.007; p = 0.001) and smoking (OR: 1.690, 95% CI: 1.061-2.693; p = 0.027) were associated with nocturia severity. CONCLUSIONS: MetS and smoking doubled the risk of moderate/severe nocturia in patients with LUTS and BPE. Assessing smoking and metabolic status in LUTS/ BPE patients is suggested.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. De Nunzio C, Brassetti A, Proietti F, et al. Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement. Prostate Cancer Prostatic Dis. 2017. PMID: 29203892. doi:10.1038/s41391-017-0003-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。